State Policies of Medical Marijuana versus Food & Drug Administration Policies of Pharmaceutical Drugs by Stephan, Kayla
Rochester Institute of Technology 
RIT Scholar Works 
Theses 
6-2019 
State Policies of Medical Marijuana versus Food & Drug 
Administration Policies of Pharmaceutical Drugs 
Kayla Stephan 
kms2475@rit.edu 
Follow this and additional works at: https://scholarworks.rit.edu/theses 
Recommended Citation 
Stephan, Kayla, "State Policies of Medical Marijuana versus Food & Drug Administration Policies of 
Pharmaceutical Drugs" (2019). Thesis. Rochester Institute of Technology. Accessed from 
This Thesis is brought to you for free and open access by RIT Scholar Works. It has been accepted for inclusion in 










Master of Science, Science, Technology and Public Policy  
Thesis Submitted in Partial Fulfillment of the Graduation Requirements for the 
 
College of Liberal Arts/Public Policy Program at 
ROCHESTER INSTITUTE OF TECHNOLOGY 











Sandra Rothenberg           
Department Chair / Thesis Advisor    Signature   Date 
 
 
Franz Foltz           
Committee Member      Signature   Date 
 
 
Joan Adamo           





Table of Contents 
Abstract……………………………………………………………………...…………………….3 
Chapter I. Introduction…………………………………………………………………………….4 
Chapter II. Literature Review……………………………………………………………………..7 
Chapter III. Research Questions ………………………………………………………………...16 
Chapter IV. Methodology………………………………………………………………………..17 
Chapter V. Results……………………………………………………………………………….20 
 FDA Regulations………………………………………………………………………...20 
 State Level Regulations of Medical Marijuana………………………………………….27 
 Comparison………………………………………………………………………………29 
Chapter VI. Analysis……………………………………………………………………………..41 
Chapter VII. Discussion and Conclusion...…………………………………………………..…..46 
 Limitations……………………………………………………………………………….48 
 Implications for Future Research………………………………………………………...49 









In the past 22 years, 32 states have legalized and regulated marijuana for medical use. 
However, marijuana is scheduled as a Schedule I drug according to the federal government. This 
means that states have no specific regulations to follow for regulating marijuana for medical use. 
Because of this, states may be risking the safety of medical marijuana patients. Research was 
conducted to analyze the policies set out by the Food & Drug Administration (FDA) regarding 
the regulation of a prescription drug. Since the FDA is responsible for the safety and efficacy of 
prescription drugs, this analysis included what types of risks were mitigated by FDA policies. 
State policies on medical marijuana were then compared to FDA policies in order to determine if 
aforementioned risks are being acknowledged and mitigated by states. This research found that 
states are implementing some policies similar to aspects of FDA regulations, but states are not 
eliminating nearly as many safety risks that the FDA focuses on eliminating. States are, however, 
creating additional policies that encompass social issues regarding the legalization of medical 
marijuana, which the FDA doesn’t do, which could be allowing medical safety to be analyzed in 




Chapter I. Introduction 
 
The use and acceptance of medical marijuana in the United States is evidenced by an 
increasing number of states that have passed legislation to legalize its use. While there is a long 
history of pharmaceutical regulation in the United States, medical marijuana is illegal at the 
federal level of government. Thus, regulation rests at the state level, where there are significantly 
different regulatory standards across these states. The level and type of regulation for marijuana 
as a medication across all states is significantly less than the level of regulation for traditional 
pharmaceuticals.  
Marijuana is considered a Schedule I drug and thus illegal at the Federal level of 
government. According to the Drug Enforcement Administration, a Schedule I drug is a drug 
“with no currently accepted medical use and high potential for abuse” (U.S. Drug, 2018). This 
classification aligns marijuana with drugs like heroin, ecstasy, and lysergic acid diethylamide 
(LSD). However, in 1996, California passed Proposition 215 which legalized the medical use of 
cannabis. By 1998, three additional states (District of Columbia, Oregon, and Washington state) 
had also legalized marijuana for medical use. President Clinton, however, reiterated his 
opposition to medical marijuana use and threatened to take away the prescribing rights of doctors 
who suggested medical marijuana use to their patients. A group of physicians in San Francisco, 
however, challenged this and prevailed in Conant v. McCaffrey. This case prohibited the 
punishing of physicians or taking their DEA licenses for recommending medical use of 
marijuana (Conant, 2000). In 2005, during the Bush administration, Gonzales v. Raich ruled in 
favor of the federal government’s ability to enforce federal laws in states that had already 
legalized medical marijuana, specifically in terms of production and use of homegrown 
marijuana (Gonzales, 2005). In 2014, during the Obama administration, the Rohrabacher-Farr 
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amendment was finally passed, after being defeated 6 times since 2001. This amendment 
describes how the Justice Department is prohibited from spending funds to interfere with the 
implementation of state medical marijuana laws. The passing of this amendment was the first 
time in Congress’ history that voting swayed to protect medical marijuana patients, and was 
viewed as a historic victory for those patients.  
In the five years since 2014, 11 states have implemented medical marijuana policy. This 
is a large yearly increase when compared to the 21 states that implemented policies in the 18 
years prior to the passing of the Rohrabacher-Farr amendment. Although more states are passing 
policies regarding medical marijuana, states are not doing so consistently. The Food & Drug 
Administration (FDA) has a specific protocol for regulating medical drugs. However, due to the 
duality of legalization in the United States, the FDA is not allowed to regulate the use of medical 
marijuana and it continues to prove difficult for states to regulate in a standardized manner. 
While this may prove to be good for policy innovation, it is unclear if the risks associated with 
the lack of standards should or can be remedied. While there is variation between state policies 
for medical marijuana regulation, the regulation for pharmaceutical drugs are clear and outlined 
by the FDA. The FDA uses the Code of Federal Regulations to publish the regulations for 
regulating drugs for medicinal use.  
In this thesis, I will be looking at the difference between the standards of traditional 
pharmaceutical regulation and the current state of regulation of medical marijuana across a 
number of states. This is important to study because states currently have no standardization for 
regulating medical marijuana, which could be jeopardizing the safety of medical marijuana 
patients. I will identify the goals of different regulatory steps in the traditional processes, and 
compare these steps to current state regulations of medical marijuana. Through this comparison, 
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I will identify where current medical marijuana law may be lax, and perhaps inadequately 
protecting the safety of patients. I will then compare this to what is currently known about the 
impacts of state legalization to see if any of these potential problems have come to fruition. 
The next section will be a review of previous research conducted on the implications of 
medical marijuana legalization. From this literature, I will identify my specific research 
questions, outline a methodology for data collection, and describe the data and findings of 







Chapter II. Literature Review 
 Since medical marijuana is approved as a medicinal drug in many states, it is important to 
look at the known risks of this type of drug. The purpose of this literature review is to see what 
studies have been conducted on the risks associated with medical marijuana legalization. It 
analyzes the most common impacts on society that has been studied thus far, including increased 
use of recreational marijuana, youth use, public health effects, traffic fatalities, crime and suicide 
rates, and more.   
Methodology 
 I focused my search results on the implications of implementing medical marijuana laws. 
Utilizing Google Scholar, research was conducted to find only the implications of medical 
marijuana once a law or policy was implemented. Some research spanned the United States, 
while other research only touched a specific group of states, or one single state. Additionally, 
research spans the whole history of medical marijuana, which is a fairly short timeline (2004-
2017). During a preliminary search, I found multiple categories of outcomes studied, including 
increased use of recreational marijuana, youth use, crime, public health effects, traffic fatalities, 
suicide, and a change in attitude. Once I discovered the main topics, I delved into them 
individually. This search included phrases like “legalization of medical marijuana on crime” and 
“legalization of medical marijuana on suicide rates.” All of the statistics of these implications 
were studied after the implementation of medical marijuana laws and compared to what the 
statistics were prior to the implementation of the laws.  In this review, I have excluded any 
research that was not exclusively about medical marijuana. This included any papers analyzing 
effects of marijuana in general, as well as papers discussing implications of legalizing marijuana 
for recreational use. While some academic scholarship focused on the ethical dilemma and 
8 
 
duality of medical marijuana legislation in the United States, I will not consider the research on 
ethics, and instead will focus on the seven main categories of study regarding the implementation  
of medical marijuana laws. 
Findings 
Summary 
 The seven main categories of research on the impacts of medical marijuana legalization 
are: increased use of marijuana, increased youth use (particularly adolescents), effects to the 
public health system, traffic accidents & fatalities, crime rates, suicide rates and a change in 
attitude regarding marijuana. A total of 25 articles were found covering these topics. Across the 
25 articles, a few revolved around each topic—with the most research being conducted on 
increased youth use and traffic accidents and fatalities. Table 1 shows the topics covered in each 
of the articles reviewed.  Additionally, Table 2 shows the general findings of each category, 






























Citation          
Anderson 
(2013) x         
Anderson 
(2014)  x        
Bradford 
(2016)   x       
Cerda (2011)    x      
Choo (2014)     x     
Chu (2014)      x    
Davis (2016)   x x      
Friese (2012)     x     
Grucza (2015)  x        
Hasin (2015)    x      
Khatapoush 
(2004)       x   
Lynne-
Landsman 
(2013)     x     
Masten (2014) x         
Miech (2015)     x  x   
Morris (2014)      x    
Rylander 
(2014)  x        
Salomonsen-
Sautel (2014) x         
Salomonsen-
Sautel (2012)     x     
Santaella-
Tenorio (2017) x         
Sevigny (2014)        x  












Youth Use 5 Mixed No correlation for national sample. Increased 
use when looking at specific region. 
Traffic 
Incidents 
4 Mixed Lower fatality rates, but higher number of 
marijuana-positive drivers in accidents. 
Increased Use 3 Mixed Increased use for national sample. No 
correlation when looking at specific regions. 
Suicide Rates 3 Mixed No correlation in one national study and in 




2 Positive Decreased perceived harm. 
Public Health 
Effects 
2 Mixed Lower prescription drug use and increase in 
hospital admissions.  
Crime Rate 2 Mixed Increase in marijuana arrests, but no correlation 
to other crimes. 
 
Increased Use 
 Two articles utilized the National Epidemiologic Survey on Alcohol and Related 
Conditions to determine if use of marijuana increased after medical marijuana laws were 
implemented (Cerda, 2011; Hasin, 2015). It was concluded that recreational marijuana use more 
than doubled after the implementation of policies regarding medical marijuana. In addition, the 
likelihood of marijuana abuse/dependency increased in states with medical marijuana laws. 
However, a study conducted in California (Khatapoush, 2004) found no increase of drug use 
after the implementation of medical marijuana laws. This is likely because of the decreased 
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sample size. This research demonstrates that policy makers should be aware of potential overuse 




 Two articles analyzed increased youth use of marijuana across multiple states (Choo, 
2014; Lynne-Landsman, 2013). Using surveys, there was no statistically significant difference in 
marijuana use before and after policy change or implementation. Two other articles conducted 
surveys in one specific state (Friese, 2012; Miech, 2015). When research was conducted with a 
narrower sample size of just one state, more statistically significant results were found. In 
Montana (Friese, 2012), 31% of 8th, 10th, and 12th grade students reported having had used 
marijuana in their lifetime. Similarly, in California and after the decriminalization of marijuana 
(Miech, 2015), 25% of 8th, 10th, and 12th graders said they were more likely to have used 
marijuana in the past 30 days.  One study conducted research in the Denver metropolitan area 
and found that 74% of adolescents had used someone else’s medical marijuana (Salomonsen-
Sautel, 2012). This research shows how drastically results change based on area and local versus 
national level data. When looking at national data, the results appear to wash out. 
 
Public Health Effects 
 The legalization of medical marijuana has impacted the public health system. For 
example, one study was conducted on how the implementation of medical marijuana policies 
impacted the use of all FDA-approved prescription drugs paid for by the Medicare Part D 
program (Bradford, 2016). Using data from the Medicare Part D Prescription Drug Event 
Standard Analytic file and restricting the analysis to any prescription drugs that treated 
conditions for which medical marijuana could be a treatment, the author found that medical 
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marijuana laws caused prescriptions drug use that served as alternatives to fall drastically – with 
Medicare spending an estimated $165.2 million less than in previous years. In addition, a study 
in Colorado (Davis, 2016) found that there was an increase in hospital discharges, poison center 
calls, and decreases in treatment entries after the legalization of medical marijuana.  
 
Traffic Incidents 
 Two articles used the Fatality Analysis Reporting System collected by the National 
Highway Traffic Safety Administration to determine if there was a correlation between traffic 
incidents and the legalization of medical marijuana (Santaella-Tenorio, 2017; Anderson, 2013). 
Both found that, on average, states with medical marijuana laws had lower traffic fatality rates 
than states without medical marijuana laws. On the other hand, a study conducted in Colorado 
(Salomonsen-Sautel, 2014) found that a larger proportion of drivers in fatal motor vehicle 
crashes were marijuana-positive after commercial availability of medical marijuana increased. 
Similarly, one study of 12 states (Masten, 2014) found that only a few states—California, 
Hawaii, and Washington State—had an increased driver cannabinoid prevalence associated with 
the implementation of medical marijuana laws. 
 
Crime Rates 
 The implementation of medical marijuana laws has led to changes in crime rate. Two 
studies were conducted across the United States. One study (Chu, 2014) found that the passing of 
medical marijuana legislation led to a 10-20% increase in marijuana arrests, while the other 
study (Morris, 2014) found that medical marijuana laws were not predictive of higher crime 
rates. In particular, the study found no correlation for increased crime rates of homicide, rape, 




Suicide Rates  
 Three studies were conducted regarding suicide rates after the implementation of medical 
marijuana laws. Two of them were conducted across the entirety United States, utilizing the 
National Vital Statistics System (Anderson, 2014; Grucza, 2015). While Anderson (2014) found 
that legalization of medical marijuana was associated with a reduction in suicide rates of men 
aged 20-39, Grucza (2015) found that there was no association between medical marijuana 
policy and suicide risk in ages 15 and older. A third study (Rylander, 2014) was conducted in 
Colorado and also found that there was no significant correlation between the number of medical 
marijuana registrants and suicides. 
 
Change in Attitude 
 Two studies elaborated on the change in attitude regarding marijuana once a medical 
marijuana legislation was put into place. Both Khatapoush (2004) and Miech (2015) looked at 
California and noticed that perceived harm of medical marijuana decreased, particularly after the 
media cover of decriminalization of marijuana.  
 
Other 
 Furthermore, other categories were mentioned, but not well studied. First, one article 
analyzed how the potency of marijuana changed after the implementation of medical marijuana 
laws (Sevigny, 2014). Studying nearly 40,000 marijuana samples that were seized by law 
enforcement, it was found that potency increased by 0.5% after legalization of medical 
marijuana. This increased to 1% more potent in states that had retail dispensaries. Secondly, a 
study analyzed data from hospital emergency departments within Colorado (Wang, 2013). The 
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study found that there were higher unintentional marijuana ingestions by young children after 
decriminalization of marijuana. 
 
Discussion 
To summarize, this literature review focused on the effects of implementing medical 
marijuana policies. Some findings were consistent, while others were not. There also was not a 
large number of articles in any one category. This demonstrates just how new this topic is. 
Considering the first state to legalize marijuana for medical purposes was California in 1996, 
limiting the ability of researchers to study the impact of these laws. Overall, the research I found 
revolved around the societal impacts of implementing medical marijuana policies, such as youth 
use, traffic incidents, increased recreational use, suicide and crime rates, public health effects, 
change in attitude, potency, and pediatric exposure. While all of the categories appeared to be 
under-researched, potency and pediatric exposure proved to be even more so - by only having 
one study available on each. While this research does address some of the risks associated with 
medical marijuana legalization, there are many risks that are not considered. This includes safety, 
efficacy, and potency of medical marijuana. These are things that should be considered when 
regulating a substance as a medicinal drug. All in all, however, the majority of research appears 
to be regarding the implications of medical marijuana policies and not much regarding the safety 
or efficacy.  
Three articles analyzed the potential relationship between medical marijuana laws and 
their implications by examining the importance of policy dimensions, such as registration 
requirements, home cultivation, and dispensaries, as well as when the particular policy 
dimensions were enacted (Pacula, 2014; Cohen, 2010; Clark, 2011). There is no standard for 
15 
 
each state to follow, so there is plenty of room for discrepancies and small differences between 





Chapter III. Research Questions 
Given this literature review, it can be seen that there are gaps in the research on the 
impacts of legalizing medical marijuana. While there was a lack of research on the medical 
efficacy of medical marijuana, there was also evidence that legalizing marijuana for medical use 
has a secondary impact on society, including increased use, youth use, public health effects, 
traffic fatalities, crime and suicide rates, and more. The focus of this research on secondary 
impacts suggests that regulation of medical marijuana may serve to protect society not from the 
traditional FDA focus on safety and efficacy, but instead on the above societal impacts. Thus, 
research for this thesis will focus on answering the following:  
1) How does the regulation process of individual states compare to the FDA regulation 
processes for pharmaceuticals?  
2) What might these differences predict about potential issues of safety and efficacy, and 
how does this compare to current research findings on the issue?   
3) Do states take appropriate actions and apply certain steps to mitigate risks that are of 
most concern?   
4) Could the effects displayed in the literature review be mitigated by following FDA 





Chapter IV. Methodology 
Study Design & Data Collection 
 My research design is a comparative study that looks at the way states regulate medical 
marijuana, as compared to the regulation processes set out by the FDA. This comparison will be 
made by mapping out the regulations of the FDA and the regulations of the states of study, to 
find similarities and differences between state & federal regulations. 
 To begin, I will be looking at the National Conference of State Legislators. This will 
provide me with a starting point regarding which states have policies and regulations for medical 
marijuana. Appendix 1 is a matrix that shows which states in the United States have which type 
of cannabis policy dimensions. This shows policy dimensions such as whether states have or 
require patient registry or ID cards, if states allow dispensaries, specific medical conditions that 
medical marijuana can be used for, and whether states will recognize patients from other states. 
Analysis of state policies will be visually easier to identify from this matrix, allowing for easy 
comparison across states. 
In total, 23 states were selected for study. This included: Arizona, California, Colorado, 
Connecticut, DC, Delaware, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon, 
Rhode Island, Vermont, and Washington. The matrix in Appendix 1 also includes the specific 
piece of legislation from each state of study that legalized marijuana for medical use. Using this 
matrix, I looked into each state’s specific legislation, adding additional columns to the table that 
contain how that state legalized medical marijuana and how they regulated medical marijuana. In 
terms of state legislation of medical marijuana, this refers to a Senate or House bill, an indirect 
initiated state statute, an initiated state statute, or an initiated constitutional amendment. Some 
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states have specified the process of regulation in a separate document than that which legalized 
medical marijuana. For example, Arizona legalized medical marijuana through an initiated state 
statute, but then had a separate Senate Bill passed to discuss the regulation process of medical 
marijuana (Americans, 2018). This will also be documented for each state.  
Each state specifies which department will be responsible for regulating medical 
marijuana. This varies dramatically by state and can include the Department of Health, new 
departments like the Medical Marijuana Authority Division, the Medical Marijuana Commission, 
or the Office of Medical Cannabis. Some states also utilize the Department of Licensing & 
Regulatory Affairs. The department responsible for regulating medical marijuana and the 
specifics of each policy will be documented for each state. While the regulations vary among 
states, all state regulations do have common threads - including regulations regarding labelling, 
dispensaries, testing, and which medical conditions medical marijuana applies to. Many of these 
state regulations are similar to the Food & Drug Administration’s regulations for medical drugs. 
I will look at 23 states who have legalized and regulated marijuana for medical use. I 
have eliminated Utah and Alaska in the list of states I am analyzing; while they both have 
legalized marijuana for medical use, they have non-regulated medical marijuana programs. I also 
eliminated states that still have pending policies or states that were regulated after 2016, since 
some data is only available for medical marijuana policies implemented before 2016.  
Next, as seen in Appendix 2, I created a second matrix of all states policies versus FDA 
policies for pharmaceutical drugs. This allows for a comparison of policy dimensions of each 
state versus corresponding sections of FDA regulations of traditional pharmaceutical drugs. 
From this matrix, additional tables were created to show which states have, or don’t have, more 
specific regulations within each of those sections. Analysis was conducted to determine if the 
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gaps in state policies, or FDA policies, are unimportant or critical. This was done by assigning 
























Chapter V. Results 
FDA Regulations 
 The FDA uses the Code of Federal Regulations to publish their regulations for regulating 
drugs for medicinal use. The Code of Federal Regulations (CFR) is a codification of general and 
permanent rules and regulations published by executive departments and agencies of the federal 
government of the United States (National, 2018). It is published annually and about 10 titles are 
published on a quarterly basis. FDA regulations are in Title 21; this title governs food and drugs 
within the United States for three main agencies. Each agency has a chapter within the title. 
Chapter 1 belongs to the FDA, Chapter 2 belongs to the Drug Enforcement Agency, and Chapter 
3 belongs to the Office of National Drug Control Policy. Chapter 1 is then comprised of 1,299 
sections, with sections 200 - 370 being dedicated to regulations of pharmaceutical drugs. These 
sections are reflected below, along with their significance when it comes to regulating 
pharmaceutical drugs.  
 
Labeling 
 Part 201 of the CFR is dedicated to regulations regarding labeling. It emphasizes the need 
for drugs to be labeled with all names of the manufacturers, along with anyone else who has 
handled the drug in any way, as well as the need for the facility location in which it was 
manufactured (§201.1). The labeling regulations also include the need for National Drug Code 
numbers (§201.2). Additionally, the labels must include adequate directions for use and a 
statement of ingredients in the drug (§201.5, §201.10). The FDA also requires the label to have 
an expiration date and a lot number (§201.17, §201.18). In general, labeling requirements must 
include a summary for the safe and effective use of the drug, must be informative and accurate, 
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not promotional, false or misleading, and have no implied claims or suggestions for use if 
evidence of safety or efficacy is lacking. While it is true that proper labels give patients the 
information on how to properly take medications, the primary purpose of labeling is to give 
healthcare professionals the information they need to prescribe drugs appropriately. 
 
Prescription Drug Advertising and Prescription Drug Marketing 
 Parts 202 and 203 are dedicated to regulations regarding advertising and marketing, 
respectively.  Some states use advertising and marketing interchangeably, while the FDA has a 
clear definition of the two. Marketing is the process involving design, creation, research and data 
mining about how to best align the idea of a product with the target audience. Advertising, on the 
other hand, is the literal process of making the product known to an audience and is typically the 
description used to present the product to the general public (Concordia 2019).  
The FDA has a set of regulations specifically for advertisements of pharmaceutical drugs. 
The basics of these regulations include different types of advertisements, including product claim 
advertisements, reminder advertisements, and help-seeking advertisements. The regulations also 
include the scope of information that should be included in an advertisement. This can include 
effectiveness and side effects of the drug. While the specific regulations vary slightly based on 
the type of advertisement, the majority of the regulations are designed to ensure that there is no 
false or misleading information on any advertisement. Similar to the labelling regulations, this 
ensures that information is being portrayed to patients and healthcare professionals truthfully, 
allowing them to take and prescribe drugs correctly. 
Additionally, the FDA has a set of regulations for marketing of pharmaceutical drugs. 
The purpose of the marketing regulations are to implement the Prescription Drug Marketing Act 
of 1987 in order to protect the public, and to protect the public against drug diversion by 
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establishing procedures, requirements, and minimum standards for the distribution of 
prescription drugs (§203.2). The marketing regulations focus on reimportation, sales restrictions, 
samples, and wholesale distribution of pharmaceutical drugs. These regulations are put in place 
in order to protect the general public and their health. Marketing, and advertising, regulations 
help assure the safety, effectiveness, and security of prescription drugs by allowing people to get 
the accurate information they need to use prescriptions appropriately and improve their health. 
 
Medication Guides for Prescription Drug Products 
 Part 208 outlines the regulations for medication guides. Medication guide means FDA-
approved patient labeling conforming to the regulations outlined in Part 208 (§208.3). The 
regulations include the content and format of the medication guide, including how the guide 
should be written in understandable English, with non-technical and non-promotional wording 
(§208.20). The medication guide must also include the following headings, followed by a 
detailed paragraph answering the questions stated in the headings:  
● “What is the most important information I should know about {name of drug}? 
● What is {name of drug}? 
● Who should not take {name of drug}? 
● How should I take {name of drug}? 
● What should I avoid while taking {name of drug}? 
● What are the possible risks or reasonably likely side effects of {name of drug}?” 
(§208.20) 
The regulations also indicate when and how to distribute and dispense a medication guide, as 
well as exemptions to these regulations (§208.24, §208.26). The purpose of the medication guide 
is to inform patients and consumers of the prescription drugs of all information regarding the 
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proper use of the drug. It can be seen, with much more specific regulations here than are found in 
labelling, that medication guides are more specifically for patients. Therefore, the nomenclature, 
content, and format are all geared more toward consumers, which can be seen with the very 
specific headings. 
 
Requirements for Authorized Dispensers and Pharmacies to Distribute a Side Effects Statement 
 Part 209 outlines the requirements for distributing side effects statements and warnings. 
This section specifies content and format of the side effects statement. The content must read 
“Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-
800-FDA-1088,” and the format of said content must be a clear, single, easy-to-read line with a 
specified letter type (§209.10). Additionally, the section describes when and how to distribute 
and dispense the side effects statement (§209.11). The issuing of a side effects statement is 
important because all medications can cause unwanted side effects. Some side effects are not as 
severe as others - for example, some medications can cause a simple rash, while others can cause 
death. Regardless of the severity of a side effect, it is important that all known side effects are 
disclosed so that patients can be aware of adverse reactions that may potentially occur in their 
body while taking certain drugs, or if the patient even wants to take the drug in the first place.   
 
Current GMP in Manufacturing, Processing, Packing of Holding of Drugs; General and Current 
GMP for Finished Pharmaceuticals 
 Parts 210 and 211 are dedicated to regulations regarding good manufacturing practices 
(GMPs) during manufacturing, processing, packing and holding of drugs (§210) and for finished 
pharmaceuticals (§211). Part 210 mainly outlines the current status of GMPs, the applicability of 
GMP regulations within the pharmaceutical industry, and concludes with some definitions. Part 
211, on the other hand, details the specific organization and personnel within a quality control 
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unit (§211.22 - 211.34), as well as the design, lighting, ventilation, plumbing, maintenance of, 
and equipment type to be used in, quality control units (§211.42 - 211.72). The section also 
details production and process control of pharmaceuticals, as well as packaging and labeling 
control (§211.100 - 211.137). There are also regulations for laboratory controls, including 
testing, samples, and animals within a lab (§211.160 - 211.176). The section concludes with 
regulations regarding reporting, including equipment cleaning logs, batch production records, 
and laboratory records (§211.180 - 211.198). GMPs, and regulations for GMPs, are important in 
pharmaceutical drug manufacturing because consumers cannot easily detect an unsafe, 
ineffective, or “bad” drug by looking at it, smelling it, touching it, or even ingesting it. GMP 
testing is typically performed on small samples within a larger bath to ensure that the rest of the 
batch is high quality and safe, effective, and “good” for human use. 
 
Drugs; Official Names and Established Names 
 Part 299 describes the “official name” of a drug. This section is important to standardize 
what people are calling drugs. While a lot of pharmaceutical drugs tend to have a generic name, 
in addition to their official name, it would be confusing to have multiple different names for the 
same drug. 
 
Sections Excluded from State Analysis  
Part 205 of the CFR is regulations for state licensing of wholesale prescription drug 
distributions. The CFR states, “This part applies to any person, partnership, corporation, or 
business firm in a state engaging in the wholesale distribution of human prescription drugs in 
interstate commerce” (§205.1). Since each state has different policies on medical marijuana, 
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there is no interstate distribution, therefore making it fair that this part of the CFR is exempt from 
being analyzed. 
Part 206 of the CFR is imprinting of solid oral dosage form drug products for human use. 
While medical marijuana is allowed in pill form in many states, this FDA requirement is 
specifically for pills that are going to be introduced into interstate commerce, stating that “no 
drug product in solid oral dosage form may be introduced or delivered for introduction into 
interstate commerce unless it is clearly marked or imprinted with a code imprint” (§206.10). 
With that, and due to the lack of interstate commerce mentioned above, it is fair that this part of 
the CFR is exempt from being analyzed. 
Part 207 of the CFR outlines the requirements for foreign and domestic establishment 
registration and listing for human drugs, including drugs that are regulated under a biologics 
license application, and animal drugs, and the National Drug Code. The purpose of this part is to 
register establishments that manufacture, repack, relabel, and salvage drugs. The FDA keeps 
record of this, as well as drug listing information, allowing the FDA to have a current inventory 
of drugs that are manufactured, repacked, relabeled, or salvaged for commercial distribution and 
where. According to the FDA, “the information facilitates implementation and enforcement of 
the Federal Food, Drug, and Cosmetic Act and is used for many important public health 
purposes” (§207.5). States each have their own way of registering dispensaries, and 
manufacturers or medical marijuana, since states have a variety of different agencies in charge of 
their medical marijuana programs.  
The following parts are not analyzed due to the lack of applicability to medical 
marijuana: Part 212, regarding good manufacturing practice for positron emission tomography 
drugs; Part 216, regarding human drug compounding; Part 225, regarding good manufacturing 
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practice for medicated feeds; Part 226, regarding good manufacturing practice for type A 
medicated articles; Part 250, regarding special requirements for specific human drugs; and Part 





State Level Regulations of Medical Marijuana 
 Each state with medical marijuana policies creates their legislation and regulation in a 
different way. Within the past 22 years, 32 states have legalized and regulated marijuana for 
medical use. In terms of how that state legalized medical marijuana, 15 states legalized through a 
Senate or House bill. Similar to the United States government, this means that the Senate or 
House within the state’s legislature proposes the bill and both parties must agree on it. After that, 
it can be signed by the governor to turn into law. Three states legalized medical marijuana 
through an indirect initiated state statute, which is initiated by citizens through the collection of 
signatures. After that, the state legislature can alter it, deny it, pass it, or draft a new copy and 
post both on a ballot for voters to decide upon. Four states legalized medical marijuana through 
an initiated state statute, which is similar to an indirect initiated state statute, except it goes 
directly from the collection of signatures to the ballot for a vote. Three states have legalized 
through an initiated constitutional amendment, which is similar to the state statute but it directly 
amends that state’s constitution and the exact process varies by state. Some states have specified 
the process of regulation in a separate document than that which legalized medical marijuana. 
For example, Arizona legalized medical marijuana through an initiated state statute, but then had 
a separate Senate Bill passed to discuss the regulation of medical marijuana (Americans, 2018). 
Approximately half of the states that have legalized medical marijuana, however, also mentioned 
the regulation process in the same document.  
Within the regulation documents, each state specifies which department in each state will 
be responsible for regulating medical marijuana. This varies dramatically by state. Some states 
utilize the Department of Health, like Oregon and Hawaii. Other states create new offices and 
departments that typically fall under the Department of Health. This includes Minnesota, which 
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calls their new department the Office of Medical Cannabis. Other states, such as Michigan and 
Connecticut, use the state’s current Department of Licensing & Regulatory Affairs. Some states 
even use the Department of Agriculture, such as Illinois and California. Other states also use a 
combination of multiple state departments involved in the regulation. While the regulation 
specifically varies between each state, all states that have regulation do have some common 
threads - including labelling, dispensaries, testing, and which medical conditions medical 







 To some degree, many FDA regulations are reflected within the state regulations. Table 3 
shows FDA regulations and states that have policies correspond to different areas of FDA 
pharmaceutical regulation. The sections below will more specifically discuss which FDA 
regulations overlap with state policies. Tables 4 through 9 are derived from Table 3, breaking 
down each FDA policy into a more specific table. 
 




AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Labeling x x x x x x x x x x x x x x x x x x x x x x x 
Prescription 
Drug Advertising x x x x  x x    x x x x  x x  x x   x 
Prescription 









Distribute a Side 
Effects Statement    x x      x  x   x x x x  x   






 x x x  x   x x x x x x x x x x x x x  x 















 The labeling section of the CFR is broken into specific regulations that the FDA is 
required to follow when regulating pharmaceutical drugs. There is some overlap when it comes 
to states following these specific regulations in their regulation of medical marijuana. Table 4 
shows the specified regulations and which are common, or uncommon, amongst states. All 23 
states have regulations regarding the labeling of medical marijuana. 19 of 23 states also require 
medical marijuana labels to have the name and location of the business manufacturer, packer, or 
distributor. Additionally, 16 of 23 states have regulations regarding the clear statement of 
ingredients on the label. Another common regulation is the significance of control numbers. 18 
of 23 states require labels to have a control, lot, harvest, or batch number that can be easily 
tracked back to the manufacturer, distributor, and facility. 13 of 23 states also have regulations 
regarding the truth and accuracy of all statements on the label. Some less common regulations 
include the label having adequate directions for use, which was implemented in 7 of 23 states; an 
expiration date, which was implemented in 10 of 23 states and is optional in Washington state. 
Specific formatting, which is referred to as “Prominence of required label statements” was 
implemented in 3 of 23 states. Some aspects of FDA pharmaceutical regulations are not reflected 
in state policies at all, including National Drug Code numbers and Spanish-language versions of 
required statements. However, it is understandable that medical marijuana doesn’t not have 
National Drug Code numbers because it is nationally labelled as a Schedule I drug.  
In addition to states adopting some FDA regulations, some states have also implemented 
supplemental regulations. Table 4 summarizes the labeling regulations for each state. Above the 
colored line is policies found in the FDA standards, while below the colored line are additions 
made by states not found in FDA standards. This includes regulations such as the printing of 
patient name or registry identification number on the label, which was implemented in 10 of 23 
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states; an allergen warning, which was implemented in 8 of 23 states; and the list of all non-
organic products used in the cultivation of medical marijuana, which was implemented in 4 of 23 
states. 15 of 23 states have added a regulation of labeling the medical marijuana with the specific 
strain or potency of the marijuana. 17 of the 23 states require the label to have the net weight or 
quantity of marijuana in the package that is being labelled. Additionally, 13 of 23 states require 
the label to be not attractive to children, and many states include the complete omission of any 





Table 4: Labeling Regulations of States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Name & Place of 
manufacturer, packer, or 
distributor x x x x  x x x x x x x x x  x x x x  x  x 
National Drug Code 
numbers                        
Adequate directions for 
use    x   x    x  x   x  x   x   
Misleading statements  x x   x   x x x  x x  x x   x x  x 
Statement of ingredients  x x x x x x x x x x x x x  x x   x    
Prominence of label 
statements   x        x   x          
Spanish-language                         
Location of expiration 
date    x   x x  x x x    x  x x  x  optional 
Significance of control 
numbers x x x x x  x   x x x x x x x x x x  x  x 
Additional Policies Added by States 
Patient's Name or 
Registry ID Number x  x x  x    x x  x   x x  x     
Shall not be made 
attractive to children  x x    x   x x x x x x x    x x  x 
Allergen Warning  x    x  x  x x x  x  x        
Net Weight   x x  x x  x x x x x  x x x x x x  x  x 
List of cultivation 
nonorganic pesticides, 
fungicides, & herbicides    x   x   x            x   
Date of Dispensing   x x  x x x   x x x x  x x x x  x  optional 




Prescription Drug Advertising and Prescription Drug Marketing 
 The CFR is broken into both an advertising section and a marketing section. 14 of the 23 
states have regulations regarding marketing and advertising. However, seven of the states with 
advertising and marketing regulations encompass marketing and advertising into one category, as 
opposed to separating them.  Another six of the states only have advertising requirements, and do 
not mention marketing at all. Oregon is the only state with both advertising and marketing 
requirements. Montana is the only state with only one advertising regulation, which is that 
advertising is prohibited. No states have regulations regarding the use of the drug’s official name 
on the advertisement or regulations regarding the ingredients of the drug on the advertisement 
having to match that on the label. 10 of the 23 states have regulations regarding the truth and 
accuracy of statements on advertisements, and 5 of the 23 states have regulations outlining 
different types of advertisements. Only four states have regulations regarding samples of medical 
marijuana being used for marketing. Of those four, three states have only one regulation: samples 
for marketing purposes are prohibited. 9 of 23 states do have some type of regulation regarding 
the maintenance, security, or content of records and receipts, similarly to FDA regulations. No 
states, however, have any marketing regulations regarding re-importation or sales restrictions.  
 In addition to states adopting some FDA regulations, some states have also implemented 
supplemental regulations. In Table 5, all regulations below the colored line are additions made 
by states. Six states implemented a policy that prohibits advertisements and marketing to be 
toward minors. Three states do not allow advertisements to encourage the use of medical 
marijuana for anything other than that states’ approved list of debilitating medical conditions. 
DC has a marketing policy that indicates that dispensaries must have a plan for marketing prior 
to becoming an approved dispensary.
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Table 5: Marketing and Advertising Regulations of States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Advertising Guidelines 
No "unofficial" names              
Advertising is 
prohibited 
         
Ingredients must match label                       
Types of Advertisements  x           x  x x      x 
Misleading Statements  x x x  x x    x x      x x   x 
Marketing Guidelines 
Reimportation                        
Sales Restrictions                        
Samples  x*              x*   x*    x 
Wholesale Distribution                    x   x 
Request & Receipt Forms, Reports and 
Records      x     x x x x  x x  x    x 
Additional Policies Added by States 
Ads cannot encourage use of marijuana for 
anything other than debilitating medical 
conditions    x       x         x    
Dispensary application must offer a 
marketing plan      x                  
No advertising or marketing to minors  x         x x    x    x   x 








Medication Guides for Prescription Drug Products 
 Of the 23 states being analyzed, only five states have policies regarding medication 
guides for medical marijuana, which can be seen in Table 6. These states typically refer to them 
as patient education, or patient information. The FDA only breaks their regulation into two parts: 
content and format. Their content is quite extensive and while four states have regulations 
regarding what specifically needs to be in their patient educational materials, the regulations are 
nowhere near as extensive as the FDA. Only one state requires a specific format, mostly 
specifying font size and type, and not specifying headings or organization - like the FDA 
regulations do. Vermont is the only state that has no content or format regulations, but does 
specifically state that dispensaries are required to provide patient educational materials. Maine 
and Massachusetts also require the distribution of patient educational materials, while New 
Hampshire and New Jersey just require the materials to be available for qualifying patients and 
caregivers. 
 
Table 6: Medication Guide Regulations for States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Content         x  x     x x       
Format                x        
Distributing / 




Requirements for Authorized Dispensers and Pharmacies to Distribute a Side Effects Statement 
 There are nine states that have regulations regarding the distribution of a side effects 
statement. Similar to the FDA regulations for medication guides, the FDA only breaks their 
regulations into two parts for side effects statements: content and format. 7 of the 23 states have 
content regulations, but four of those states only have the content of their side effects section 
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requiring a statement regarding the limited information available on the side effects of medical 
marijuana. No states have formatting regulations, while 4 of the 23 states have regulations about 
how to distribute or dispense the side effects statement. 
 In addition to states adopting some FDA regulations, some states have also implemented 
supplemental regulations. In Table 7, the regulation below the colored line is an addition made 
by states. 2 of the 23 states require any side effects statement to be true, accurate, and not 
misleading. 
 
Table 7: Side Effects Regulations for States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Content     x      x-  x-   x- x x x-     
Format                        
Distributing 
/ Dispensing     x            x x   x   
Additional Policies Added by States 
True / Not 
Misleading    x               x     
x- = while there is a regulation in place, the content states: “There is limited information 
available on the side effects of medical marijuana” 
 
 
Current GMP in Manufacturing, Processing, Packing of Holding of Drugs; General and Current 
GMP for Finished Pharmaceuticals 
 The GMPs sections of the CFR is broken into specific regulations that the FDA is 
required to follow when regulating pharmaceutical drugs. There is some overlap when it comes 
to states following these specific regulations in their regulation of medical marijuana. 18 of the 
23 states have regulations regarding GMPs. Table 8 shows the specified regulations and which 
regulations are common, or uncommon, amongst states. 8 of the 23 states have a general 
regulation as to how the quality control unit must be organized and 12 of the 23 states have 
regulations regarding personnel. These regulations vary, as some states have outlined very 
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specific training, specific onboarding processes, and others have extensive background checks 
and files on all personnel. The FDA also specifies building or facilities design and maintenance, 
and 13 of the 23 states have regulations regarding their facilities. However, these regulations are 
not specific, since some states only specify the sanitation of the building, or describe that the 
building must be deemed safe by fire and town officials, or be suitable for the manufacturing, 
packaging, or dispensing of medical marijuana. Similarly, 14 of the 23 states have regulations 
regarding the equipment used in the facility - however, they are also vague, and most only 
specify that the equipment should be sanitary. Laboratory controls and record keeping are both 
common regulations, as 18 of 23 states have regulations regarding them. Since only four of 23 
states have a regulation regarding holding/distribution and only 3 of 23 states have a regulation 
regarding production & process controls, these are much less common amongst states. 
Some states have also implemented regulations that go beyond FDA standards. In Table 
8, all regulations below the colored line are additions made by states. This includes regulations 
such as security equipment being on the premises, which has been implemented in 18 of 23 
states; specific waste disposal regulations, which has been implemented in 13 of 23 states; and 
location of dispensaries or other facilities in relation to schools, churches/other places of 
worship, or pre-designated drug-free zone, which has been implemented in 14 of 23 states. 
Distance between the medical marijuana facility and off-limits location varies, from a 50-foot 
radius, to 300 feet away, to 1000 feet away. Some states even include public swimming pools, 
playgrounds, and day-care facilities in their regulations (NV). 
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Table 8: Good Manufacturing Practices Regulations of States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
QC Organization         x  x x  x   x x  x    x 
QC Personnel   x      x  x x  x x  x x x  x x  x 
Buildings/Facilities Design and Maintenance   x   x     x x x  x x x  x x x x  x 
Equipment Requirements   x x  x    x x x x x  x  x x x x  x 
Drug Storage (Containers and Closures)   x x  x   x x x x x   x x x x  x  x 
Production & Process Controls          x   x    x       
Packaging and Labeling Control  x x x  x    x x x x  x x x x x x x  x 
Holding/Distribution    x      x x  x           
Laboratory Controls  x x x  x    x x x x x x x x x x x x x  x 
Records and Reporting  x x x  x    x x x x x x x x x x x x x  x 
Additional Policies Added by States 
Security  x x x  x   x x x x x x x x x x x x x  x 
Waste Disposal   x x  x   x x x x x   x  x x  x  x 
Distance from School  x x x  x   x  x  x x x x x  x  x  x 
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Official and Established Drug Names 
 The FDA section regarding established names of drugs specifies that pharmaceutical 
drugs should use their official name and avoid the use of “other names.” 21 of the 23 states being 
analyzed have regulations regarding the definition of medical marijuana and regulations to avoid 
the use of street names, and use only the defined definition of medical marijuana in that specific 
state, which can be seen in Table 9. Nevada and Montana are the only states that do not specify 
the definition of their medical marijuana. 
 
Table 9: Drug Name Regulations of States 
 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Official 
Name x x x x x x x x x x x x x   x x x x x x x x 
Avoid Use 
of "Other 
Names" x x x x x x x x x x x x x   x x x x x x x x 
 
 
Other Regulations Added by States 
 In addition to states adopting policies that compare to FDA regulations, states have 
implemented additional policies related to medical marijuana that focus less on safety and more 
on the social aspects of medical marijuana. Table 10 shows these additional regulations and 
which states have implemented a policy for each regulation. 10 of 23 states have implemented a 
policy regarding the anti-discrimination of employees. This means that states are not allowed to 
deny employees because of their status as a medical marijuana patient. 11 of 23 states have 
implemented policies regarding employee drug tests. 5 of 23 states have a policy that they cannot 
deny or fire employees based on a marijuana-positive drug test, if they are medical marijuana 
patients. 6 of 23 states have a policy that they can deny or fire employees for a marijuana-
positive drug tests, regardless of their status as a medical marijuana patient. 9 of 23 states have a 
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policy that prohibits the smoking or vaping of medical marijuana in various public places. 9 of 
23 states have a policy regarding impaired driving. For five of those states, the policy is zero 
tolerance – meaning driving under the influence of marijuana, even if one is a medical marijuana 
patient, is illegal. However, the other four states have a policy that allows medical marijuana 
patients to have a minimal amount of marijuana in their system while driving. 
 
Table 10: Additional Regulations Added by States 
 
States 









Tests x    x      x  x        x   
Positive Drug 
Test 
(Employers)  x  x         x      x  x    x  
Prohibits 
Smoking/Vaping 
in one or more 














amount allowed)   x           x x        x 
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Chapter VI. Analysis 
 
 State regulations regarding medical marijuana have some variation, particularly when 
compared to specific sections of the FDA’s CFR for pharmaceutical drugs. However, states are 
implementing additional policies that go beyond the FDA regulations, allowing for the 
mitigation of additional risks associated with medical marijuana legalization. As seen in the 
literature review, studies found that safety and efficacy, increased use, youth use, public health 
effects, traffic incidents, crime rates, and suicide rates were common concerns associated with 
the legalization of medical marijuana. Many, although not all, of these concerns are addressed in 
state legislation. This can be seen, for example, with the additional policies added by states 
revolving around children, such as the distance of facilities from a school and not advertising to 
minors. These policies are geared specifically toward decreasing increased youth use. 
 
Labeling 
 Within the labeling section, states have adopted a majority of the regulations already set 
out by the FDA for pharmaceuticals. The few regulations that are not being adopted include the 
use of National Drug Code numbers and a Spanish-language version of certain required 
statements. Since medical marijuana is still illegal on a federal level, it is impossible for states to 
use National Drug Code numbers. Many FDA regulations regarding labeling are reflected in 
state regulations. Labeling requirements are important to ensure the product is safe and patients, 
caregivers, physicians, manufacturers, and dispensaries are getting accurate information about 
the products. Some states have implemented additional policies including adding the patient’s 
name or registry ID number to the label, as well as an allergen warning, the net weight or 
quantity, date of dispensing, strain/potency, and list of all non-organic pesticides, fungicides, and 
herbicides used during cultivation - as seen in Figure 3. The implementation of these policies 
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adds an additional level of safety to medical marijuana. Considering the reason that the FDA has 
policies on labeling is to ensure product safety, the states are adding policies to their legislation 
that is applicable to medical marijuana and continues to ensure the safety of the product. An 
important added regulation in 13 of the 23 states is that labels cannot be made attractive to 
children, including the complete elimination of color or cartoons. This helps mitigate the 
commonly seen risk of increased youth use. More states should adopt a policy regarding the 
labels being unappealing to children, and the FDA could also learn from this. According to the 
National Survey on Drug Use and Health from 2014, nearly 6,000 youth reported using 
prescription pain relievers without a doctor’s guidance for the first time (Volk, 2014). 
Additionally, in 2017, there were 1,031 reported prescription drug overdoses in teens (age 15-
24), while there were no reports of teens or young adults dying from a marijuana overdose (The 
National Institute, 2017). Since it is reported that marijuana overdoses are uncommon, but 
prescription drug overdoses are common, the FDA could think about implementing policies 
regarding distance of facilities, pharmacies, etc. from schools and other places that children, 
teens, and young adults frequent. 
 
Marketing & Advertising 
 While the FDA separates marketing and advertising regulations into separate sections, 
states consider them to be the same. With that, the states that have marketing and/or advertising 
regulations tend to focus more on advertising instead of marketing. Even then, the states focus on 
the advertisements being true, accurate and not misleading, as well as keeping records of sales 
and being able to report to the local government if requested. This is important, considering the 
regulations regarding advertising also revolve around product safety and ensuring that patients, 
caregivers, physicians, manufacturers, and dispensaries are getting accurate information about 
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the products. Having true, accurate, and not misleading advertisements is key when it comes to 
getting accurate information. Routine reporting also plays a key role in product safety, so the fact 
that states keep records is also important. States also implemented additional marketing or 
advertising regulations, such as prohibiting advertisements from encouraging use for anything 
other than that states list of medical conditions and prohibiting advertising and marketing to 
minors. These regulations mitigate risks that the FDA doesn’t focus on, such as increased use 
and youth use, respectively. As with the labeling requirements, the FDA could adopt similar 
policies for prescription drugs.  
 
Medication Guides 
 Medication guides are required by the FDA for every prescription drug. The FDA also 
outlines how and when the medication guides are to be distributed to patients. However, only 
five states have a policy regarding medication guides, which they often refer to as patient 
education materials or patient informational guides. The FDA has very specific content and 
format for medication guides, giving exact headlines that need to be in the guide and font size. 
The states have more vague regulations, often neglecting format entirely and having a basic 
content outline. Medication guides are important to give patients, caregivers, and physicians 
accurate information about the drug. Since there are differences in strain and potency of medical 
marijuana, medication guides should be even more necessary and states are highly lacking in this 
respect. 
 
Side Effects Warning 
 The data shows that states are lax on requiring a side effects warning, which are required 
for all drugs by the FDA; only 9 states have adopted a similar policy for medical marijuana. 4 of 
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the 23 states only have a regulation stating that the side effects warning must read “There is 
limited information available on the side effects of medical marijuana.” Issuing a side effects 
warning is important so that patients know what could potentially happen while taking the drug. 
However, the majority of known side effects come about through clinical trials. Since clinical 
trial data is required for all prescription drugs to be approved by the FDA, it is an important step 
that states are missing during their legalization of medical marijuana. However, states are not 
legalizing medical marijuana the same way the FDA legalizes prescription drugs. Instead, states 
legalize medical marijuana through Senate bills, constitutional amendments, etc., meaning states 
are less aware of potential side effects.  
 
Good Manufacturing Practices 
 In terms of good manufacturing practices (GMPs), states have adopted many policies 
similar to the FDA. GMPs are important to ensure the safety of the product, so it is important 
that states are following these procedures. There are a few states (Arizona, Vermont) that 
actually don’t have any GMP regulations addressed and these states should absolutely add some, 
since GMPs are important in product safety. States have also implemented security measures at 
their manufacturing and/or dispensing facilities, which is important since marijuana is still a 
Schedule I drug according to the federal government. The security measures ensure that only 
authorized personnel are entering the facility, adding an extra safety measure to the 
manufacturing and dispensing of medical marijuana. Additionally, many states added policies 
regarding waste disposal. Similar to the security measures, disposing of marijuana must be 
addressed since it is federally illegal. Lastly, another commonly added policy is in regards to 
facilities’ distances from a school, church, place of worship, playground, daycare center, or 
another already identified drug-free zone. This addresses a concern specific to legalizing medical 
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marijuana, which is increased youth use of marijuana. Requiring facilities to be distanced from 
places that are frequently occupied by children could help to mitigate this risk. For the most part, 
however, states have adopted many aspects of the FDA regulations regarding good 
manufacturing practices.  
 
Official Drug Names 
 The FDA regulates the use of official drug names and not using any other names that are 
not considered “established” for that drug. This is important since it would be confusing to have 
many different names for the same drug. However, there is no official definition or name for 
medical marijuana, since there is a slight variation between states. With that, there is no 
standardization for what is considered to be medical marijuana and what is not. Regulating at the 
federal level could definitely help in this respect, since the FDA would be able to standardize this 
definition, allowing for less variation. Along similar lines, there is no consensus between states 
regarding which medical conditions can be treated using medical marijuana. For example, while 
most states have a list with similar conditions on them, Maine has no list of approved conditions 











Chapter VII. Discussion and Conclusion 
Through this research, it is evident that the FDA outlines important regulations to 
regulate prescription drugs and that each regulation is in place for a reason, mitigating risks 
regarding the safety of patients and product quality. States have adopted some regulations in line 
with FDA regulations, but states have also introduced many additional areas of policy. These 
new policies mitigate additional risks, particularly in areas that are of high social concern such as 
increased drug use and youth use. For example, states with additional laws limiting advertising to 
minors and distancing medical marijuana facilities or dispensaries from schools are taking action 
to reduce the issue of increased youth use. Medical marijuana is a complex social issue. States 
can integrate potential solutions to social issues into medical marijuana policies. While states are 
creating policies for safety reasons and to maintain product quality, they have the opportunity to 
also integrate policies that address the broader social context, which is something the FDA 
currently does not do. It is in this respect that policy innovation can really happen at the state 
level.  
Since there is no level of federal standardization considering the illegality of marijuana, 
states are also creating policies that are vastly different from other states. While some of these 
discrepancies could be seen as positive policy disagreements, since states are just disagreeing 
over the scope to which medical marijuana should be regulated (Robert, 2011), the discrepancies 
should still be remedied since medical marijuana is being utilized as a medication. A remedy to 
this issue is to reschedule marijuana in a lower drug classification (Schedule II or lower). If that 
were to happen, the FDA could become involved in regulating marijuana, since it would be 
allowed for medical use. This would allow for approval of medical marijuana based on scientific 
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evidence of the benefits or negative effects, from extensive clinical trials that would be required 
by the FDA for drug approval, as opposed to political considerations.  
A commonly suggested idea to mitigate risks like increased marijuana use is to mandate 
that physicians tell their patients all of the risks of the medical marijuana they are 
recommending. Several studies (Davis, 2016; Hill, 2015; Grant, 2012) identify that the 
implementation of medical marijuana laws should come with public education of overdose 
statistics and other important information, as well as benefits/risks regarding the use of medical 
marijuana. Additionally, physicians should begin looking deeply into their patients’ history 
before recommending medical marijuana as a treatment, looking particularly at the potential for 
misuse, abuse, and addiction.  
Regarding the future involvement of the FDA in the regulation of medical marijuana, one 
idea would be for the federal government to reschedule marijuana as a Schedule II, or lower, 
drug. After that, marijuana would be eligible for use as a medical drug and the FDA would be 
involved in the regulation of the drug. The FDA requires numerous tests and trials to be 
conducted in order to determine if a drug is safe and efficacious. The FDA’s regulations would 
create much stricter rules for obtaining, taking, and prescribing medical marijuana. The 
standardized approach of the FDA could drastically decrease all of the risks felt by the states that 
have legalized medical marijuana on their own terms and increase the safety of medical 
marijuana that states are lacking. However, with marijuana’s current status, it can be seen that 
policy innovation is occurring as states build their own policies regarding marijuana for medical 
use and are allowed to look at drug safety in a broader context. However, without the 
standardization from the FDA, states are lacking in their general safety policies and potentially 




 There are some limitations to this research. First and foremost, marijuana is illegal at the 
federal level. This means that information is fairly limited in general. It also means that states 
cannot conduct as much research on marijuana. While states can still conduct FDA-approved 
clinical trials on medical marijuana, the samples must be supplied by the federal government. IN 
fact, many clinicians have complained that the federally supplied marijuana is of inferior quality, 
limiting the quality of these studies (Armentano, 2019). Additionally, the topic of medical 
marijuana is fairly new, so there is – in general – not a lot of extensive research conducted in the 
area. My research also did not analyze the quality of the regulations been compared to the FDA. 
While there was overlap between states’ regulations and FDA regulations, there was little to no 
analysis of the quality of the regulations. While I compared which states had which aspects of 
FDA regulations, there was no analysis into how the state regulations compared to the 
regulations of the FDA. Therefore, additional analysis could be conducted to determine if the 
state regulations are on the same level as the FDA or not.  
 Another limitation while conducting research was the lack of analysis of enforcement of 
medical marijuana laws. While all states have specific organizations that regulate and enforce 
medical marijuana, there was no analysis of how this occurs. Many states have multiple 
departments, or a new branch of a department, serving as the regulator and enforcer of medical 
marijuana laws. Not studying this could limit research because, while states have these policies 
in place, it is not specified how states go about ensuring the policies are enacted and done so 
properly, and up to the standards of the state.  
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Implications for Future Research 
 It is clear that additional research should be conducted regarding the implications of state 
level medical marijuana laws; much of the current research is limited and inconclusive. One 
noticed absence in existing research was a focus on potency and efficacy. This suggests that 
more research should be conducted in the realm of clinical trials. States conducting clinical trials 
on their own terms could allow policymakers to make more informed decisions on medical 
marijuana policies by using scientific evidence to back up their claims. However, because of the 
dual legality of marijuana in the United States, this will likely continue to prove to be difficult.  
Future research, on the other hand, could utilize information from other countries to make 
decisions. So far, 21 countries or territories have legalized cannabis fully or partially, for medical 
or recreational use (MacIver, 2017). Incorporating more countries in a future study could provide 
insight into the legalization of medical marijuana, as well as potential side effects or analysis of 
clinical trial studies. Many countries do not have a national agency to regulate clinical trials like 
the United States, so looking at data from additional countries that have more freedom with 
clinical trials could provide much more insight and more information than what is known in just 
the United States. 
Further research could be conducted in the realm of what the federal government can and 
cannot do to states with medical marijuana policies. While patients were given some leeway 
under the Obama administration, dispensaries are facing penalization by the federal government. 
For example, the Internal Revenue Service (IRS) has audited multiple dispensaries, referencing 
on a section of the federal tax code that prohibits companies from deducting expenses related to 
drug trafficking – alleging that dispensaries owe millions in back taxes. Steve DeAngelo, owner 
of a dispensary in California that serves more than 100,000 customers and from whom the 
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federal government says owes $2.4 million, says “No business in America could survive if all of 
its expense deductions were disallowed. This is not an attempt to tax us. It’s an attempt to tax us 
out of existence” (Scott, 2012). While states are technically allowed to make their own policies 
regarding medical marijuana, the federal government may still be making efforts to interfere. 
Additional research could be conducted to see what impact this has on states’ medical marijuana 
programs.  
Additional research could be conducted regarding the enforcement of medical marijuana 
laws within each state. Looking at whether, or not, states are abiding by the policies and doing so 
in a manner that is up to par with the states’ requirements could shed light on the actual impacts 
of the policies. Analyzing the enforcement process could determine if states are ensuring that 
policies are where they need to be and can ensure the safety of patients and product. For 
example, the Colorado Department of Agriculture takes random samples of marijuana, as it does 
for all crops. By doing so, it discovered 22 cases of pesticide misuse in 2018 (Hoing, 2019). 
While the process likely varies from state to state, studying how the enforcement occurs could 
help protect patient safety, ensure product quality, and even keep cultivation facilities and 






Implications for Policy  
Recommendation: The federal government should reschedule marijuana as a Schedule II 
or III drug, so that it can be used for medical purposes.  
While marijuana remains a Schedule I drug according to the federal government, states 
around the United States are deciding to legalize marijuana for medical—and in some cases, 
recreational—use. This is an intriguing situation, since allowing a substance to be a medicine but 
also utilized for recreational purposes really complicates the perception of the substance. One 
article (Clark, 2011) discusses the ethical, legal and medical perspectives in regards to the 
legalization of medical marijuana. Clark believes that not legalizing medical marijuana denies 
patients the right to potentially beneficial treatments and to deny them this is a violation of their 
basic human rights. Additionally, the author looks at the legal perspective – describing how, 
since marijuana is still classified as a Schedule I drug federally, it becomes difficult to formulate 
laws at a state level that do not break federal law. This gives perspective into how new policies 
should be created regarding medical marijuana. Since it is being used as a medical drug, it would 
make sense for the FDA to begin regulating medical marijuana. This would mean a rescheduling 
of marijuana as either a Schedule II or Schedule III drug. Changing the status of marijuana 
would allow physicians to prescribe medical marijuana and mean that the FDA would be 
responsible for all regulations. Additionally, advocates of rescheduling marijuana look at the 
economic impact it would have. Legalizing the use of marijuana in the United States would save 
an estimated $8.7 billion, by reducing government spending for drug enforcement in the criminal 
justice system (Miron, 2010). Legalizing drugs and taxing them in a way that is comparable to 
alcohol and tobacco would create additional revenue. Rescheduling marijuana could be a step in 
the right direction of adopting a better regulatory framework. 
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Recommendations if the federal government does not reschedule marijuana and states are 
left to continue making their own policies on medical marijuana: states need to increase the 
stringency of their regulations to ensure that safety is a higher priority. 
 There have already been multiple petitions in history to reschedule marijuana. However, 
the federal government has denied every one of them. The rescheduling process is a long and 
complicated one. Some complication comes from the idea that rescheduling requires a lot of 
input from many administrative bodies, such as the President, the Attorney General, the Drug 
Enforcement Administration, and the Department of Health and Human Services (Rough, 2017). 
If the federal government continues to deny petitions for rescheduling, the states would remain 
responsible for the regulation of medical marijuana. On one hand, this could allow states to 
innovate the way they regulate medical marijuana, allowing them to integrate new policies that 
could mitigate additional risks that the FDA doesn’t currently consider for pharmaceutical drugs. 
However, it could also mean that states continue on their current path of focusing less on safety. 
It can be seen that many states do not adopt policies along the same lines as the FDA and, while 
some do, they are not as detailed or extensive as the FDA. This could mean the addition of health 
and safety risks, since the standardization is low or non-existent. Not rescheduling marijuana 
would mean that states need to increase the rigidity of their regulations, in an effort to make sure 




 Medical marijuana is a controversial issue. The duality of legislation places marijuana on 
the federal government’s list of Schedule I drugs, while states are legalizing it on a local level. 
Previously conducted research focused on the risks that occurred after the implementation of 
medical marijuana laws. My research focused on FDA regulations for pharmaceutical drugs and 
whether, or not, states have implemented similar regulations in order to ensure the safety of 
patients and products. The FDA’s overarching mission is public health and safety, so FDA 
regulations are crucial in ensuring those goals are met. While my research found some overlap 
between state regulations and FDA regulations, it was found that states’ regulations are not 
enough to ensure the safety of medical marijuana products and patients. States are, however, 
implementing additional policies to mitigate some risks that were found to have occurred after 
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Appendix 2: FDA Sections and States that Adopted Similar Policies 
FDA Policies 
States 
AZ CA CO CT DE DC HI IL ME MD MA MI MN MT NV NH NJ NM NY OR RI VT WA 
Labeling x x x x x x x x x x x x x x x x x x x x x x x 
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